101 results on '"Motterle, G"'
Search Results
2. Radikale Prostatektomie (RP) oder Radiotherapie (RT) beim metastasierten, hormonnaiven Prostatakarzinom (PCA) mit geringer Metastasenlast: Ein indirekter Vergleich mit der STAMPEDE Studie, Arm H
3. Development and validation of a novel nomogram predicting long-term progression in patients treated with early salvage radiation therapy after radical prostatectomy: The key role of PSA kinetics
4. The key role of PSA doubling time in patients treatedwith salvage radiation therapy after radical prostatectomy: implications for the extent of radiation and the concomitant use of hormonal therapy
5. Assessing the effect of concomitant hormonal therapy on severe toxicity in patients treatedwith post-prostatectomy radiation therapy: results from a large, multi-institutional study
6. What is the optimal duration of hormonal treatment during salvage radiotherapy in men with pN1 prostate cancer? Results form a large multi-institutional series
7. Definition and impact on oncologic outcomes of persistently elevated PSA after salvage lymph node dissection for node-only recurrent prostate cancer after radical prostatectomy: clinical implications for multi-modal therapy
8. There is no way to compensate a non-timely use of early salvage radiation therapy in men with recurrent prostate cancer after radical prostatectomy. a retrospective, multi-centre analyses on oncological and toxicity outcomes
9. What is the optimal duration of hormonal treatment during salvage radiotherapy in men with pN1 Prostate Cancer? Results form a large Multi-Institutional series
10. Assessing the association between the template of pelvic salvage lymph node dissection for node-only recurrent prostate cancer and oncological outcomes. Results of a multi-institutional series
11. The key role of PSA doubling time in patients treated with salvage radiation therapy after radical prostatectomy: Implications for the extent of radiation and the concomitant use of hormonal therapy
12. Definition and impact on oncologic outcomes of persistently elevated PSA after salvage lymph node dissection for node-only recurrent prostate cancer after radical prostatectomy: Clinical Implications for multi-modal therapy
13. Comparison of salvage radiation therapy delivered for PSA persistence versus PSA relapse after radical prostatectomy: How is the outcome changing?
14. Identifying the optimal candidates for radiation therapy after salvage lymph node dissection for node-only recurrent prostate cancer after radical prostatectomy: Results from a multi-institutional collaboration
15. Assessing the effect of concomitant hormonal therapy on severe toxicity in patients treated with post-prostatectomy radiation therapy: Results from a large, multi-institutional study
16. Association between the extent of lymph node dissection and severe toxicity in men with prostate cancer treated with post-prostatectomy radiation therapy: results from a large multi-institutional series
17. Angiovac device in the treatment of renal cell cancer with cavo-athrial neoplastic thrombus
18. Assessing the impact of salvage radiation therapy field after radical prostatectomy: a long-term analysis from a large multi-institutional series
19. Multiparametric MRI of the prostate significantly underestimates tumor volume of small visible lesions. Implications for tailored focal therapy approaches
20. Are men with low risk prostate cancer but high pirads score lesions at mp-MRI still candidate for active surveillance? Results from a large, multi-institutional radical prostatectomy series
21. Persistently elevated prostate-specific antigen after salvage lymph node dissection and its impact on long-term oncological outcomes. the importance of an extensive, multi-modal approach
22. Patterns of clinical recurrences after salvage lymph node dissection for lymph-node recurrent prostate cancer and their impact on oncological outcomes. the importance of patient stratification for tailored post-operative treatments
23. How can we increase the positive predictive value of PIRADS 4 and 5 lesions at mp-MRI? Development of a novel prediction tool relying on a large, multi-institutional series
24. Changing patterns and predictors of salvage radiation therapy use over time in patients treated for post-prostatectomy biochemical recurrence: a trend analysis over a 20-year period from a multi institutional series
25. Age and Gleason score upgrading between prostate biopsy and radical prostatectomy. Is this still true in the mp-MRI era?
26. Assessing the optimal timing of salvage radiation therapy administration after radical prostatectomy: a stage-specific analysis from a large multi-institutional series
27. Long-term outcomes of clinically node-positive prostate cancer patients treated with radical prostatectomy as part of a multimodal treatment: patterns of recurrence and impact on competing-risk mortality
28. Should we target all visible areas at mpMRI suspicious for clinically significant prostate cancer in addition to the index lesion? Results from a two-institution series
29. Cure without toxicity: development of a novel model predicting trifecta outcomes after salvage radiation therapy for recurrent prostate cancer after radical prostatectomy
30. Performance characteristics of PET/CT scan in men treated with salvage lymph node dissection for recurrent prostate cancer: a per patient analysis with pathological confirmation according to each area of dissection
31. Radical prostatectomy versus radiotherapy in M1a and low volume M1b prostate cancer patients: an indirect comparison with the STAMPEDE trial arm H
32. What is the optimal surgical template for salvage pelvic lymph node dissection in patients with pelvic lymph-node recurrent prostate cancer? results from a large, multi-institutional series
33. Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost: Comparison of outcomes in a multi-institutional analysis of patients with high-risk prostate cancer
34. Assessing the optimal timing of salvage radiation therapy administration after radical prostatectomy: A stage-specific analysis from a large multi-institutional series
35. Should we target all visible areas at mp-MRI suspicious for clinically significant prostate cancer in addition to the index lesion? Results from a two-institution series
36. Assessing the impact of salvage radiation therapy field after radical prostatectomy: A long-term analysis from a large multi-institutional series
37. Patterns of clinical recurrences after salvage lymph node dissection for lymph-node recurrent prostate cancer and their impact on oncological outcomes. The importance of patient stratification for tailored post-operative treatments
38. Multiparametric MRI of the prostate significantly underestimates tumor volume of small visible lesions. Implications for tailored focal therapy approaches
39. How can we increase the positive predictive value of PIRADS 4 and 5 lesions at mp-MRI? Development of a novel prediction tool relying on a large, multi-institutional series
40. Are men with low risk prostate cancer but high PIRADS score lesions at mp-MRI still candidate for active surveillance? Results from a large, multi-institutional radical prostatectomy series
41. SC93 - Development and validation of a novel nomogram predicting long-term progression in patients treated with early salvage radiation therapy after radical prostatectomy: the key role of PSA kinetics
42. SC199 - There is no way to compensate a non-timely use of early salvage radiation therapy in men with recurrent prostate cancer after radical prostatectomy. a retrospective, multi-centre analyses on oncological and toxicity outcomes
43. SC198 - Assessing the effect of concomitant hormonal therapy on severe toxicity in patients treatedwith post-prostatectomy radiation therapy: results from a large, multi-institutional study
44. SC204 - Definition and impact on oncologic outcomes of persistently elevated PSA after salvage lymph node dissection for node-only recurrent prostate cancer after radical prostatectomy: clinical implications for multi-modal therapy
45. SC201 - The key role of PSA doubling time in patients treatedwith salvage radiation therapy after radical prostatectomy: implications for the extent of radiation and the concomitant use of hormonal therapy
46. SC197 - What is the optimal duration of hormonal treatment during salvage radiotherapy in men with pN1 prostate cancer? Results form a large multi-institutional series
47. SC263 - Persistently elevated prostate-specific antigen after salvage lymph node dissection and its impact on long-term oncological outcomes. the importance of an extensive, multi-modal approach
48. SC260 - Patterns of clinical recurrences after salvage lymph node dissection for lymph-node recurrent prostate cancer and their impact on oncological outcomes. the importance of patient stratification for tailored post-operative treatments
49. SC262 - What is the optimal surgical template for salvage pelvic lymph node dissection in patients with pelvic lymph-node recurrent prostate cancer? results from a large, multi-institutional series
50. SC267 - Assessing the impact of salvage radiation therapy field after radical prostatectomy: a long-term analysis from a large multi-institutional series
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.